	Aberrant HER2 Expression as a Specific and Feasible Diagnostic Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma. Hum Pathol Hu J, Zhang M, Meng L, Zheng L, Yang Y, Tang J, Pan X, Yin X, Yu T, Nie L, Wei Y, Zhou Q, Chen X, Chen N. PMID: 42874879 [PubMed - as supplied by publisher]
	Periprostatic adipose tissue imaging in prostate cancer: Imaging phenotypes, task-specific spatial strategies, and multicompartment integration-a critical review. Eur J Radiol Huang J, Zhang Y, Yang O, Feng Q, Du H, Gong J, Huang G. PMID: 42874220 [PubMed - as supplied by publisher]
	PANoptosis-Related Molecular Subtyping and a Subtype-Derived Prognostic Signature for Survival Prediction in Clear Cell Renal Cell Carcinoma. Technol Cancer Res Treat Wang X, Shen Y, Du S, Wang H, Xie X, He H. PMID: 42874083 [PubMed - indexed for MEDLINE]
	Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial. J Clin Oncol Solanki AA, Adams W, Proudfoot JA, Baldea K, Barkan GA, Block AM, Desai NB, Farooq A, Folkert MR, Garant A, Gorbonos A, Gupta G, Kang H, Kelly E, Kregel S, Liauw SL, Luminais CK, Mysz M, Quek ML, Showalter TN, Welsh JS, Woods M, Davicioni E, Small W Jr, Harkenrider MM. PMID: 42874014 [PubMed - as supplied by publisher]
	Educational disparities in prostate cancer survival: a retrospective cohort study from Mexico City. Salud Publica Mex Hernández-Pérez JG, Reyes-Morales H, Valenzuela-Sánchez A, Lajous M, Rodríguez-Covarrubias F, Espin-Arellano LI, Morales-Carmona E, Manzanilla-García H, Torres-Sánchez LE. PMID: 42873951 [PubMed - indexed for MEDLINE]
	Dehydrated human amniotic membrane for early return of erectile function after robotic radical prostatectomy: a 10-year journey and lessons learned. J Robot Surg Razdan S, Fathollahi A, Armache A, Razdan S. PMID: 42873363 [PubMed - indexed for MEDLINE]
	Skin-Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real-World Database Study (A Retrospective Cohort Study). Health Sci Rep Hashizume A, Kawahara T, Yamazaki M, Takamoto D, Takeshima T, Kuroda S, Uemura H, Makiyama K, Teranishi JI. PMID: 42871337 [PubMed]
	Omission of lateral isocenter shifts in robust optimization of proton therapy treatment plans for prostate cancer. J Appl Clin Med Phys O'Grady FT, Castro J, Kim DW, Fan J, Wang P. PMID: 42870582 [PubMed - indexed for MEDLINE]
	Prostate Cancer Therapy via Inhibition of Negative Immune Regulation. Biomed Res Int Dutta S, Sengupta P, Chowdhury U, Maldonado Rosas I, Kalita JC, Selvam MKP, Roychoudhury S. PMID: 42870457 [PubMed - indexed for MEDLINE]
	Liquid biopsy in bladder cancer: towards precision oncology. J Transl Med Chen C, Yang Y, Chen Z, Li X, Zhu Y, Zhai Y, Zheng J, Dai X, Zhou JG, Ma H, Ye X. PMID: 42870280 [PubMed - indexed for MEDLINE]
	Reproducibility and diagnostic performance of ADC for assessing response to neoadjuvant immunotherapy in muscle-invasive bladder cancer: a multi-ROI comparison analysis from the phase-Ib NABUCCO trial. Insights Imaging Greidanus J, Bernabei C, Chupetvloska K, Agrotis G, Mertens LS, van Rhijn BWG, van der Poel HG, van der Heijden MS, Beets-Tan RGH, Pizzi AD, Boellaard TN, Trebeschi S. PMID: 42870138 [PubMed]
	Fracture risk and fracture risk factor assessment among men at prostate cancer diagnosis. Prostate Cancer Prostatic Dis Shulman MJ, Darbinian JA, Chandra M, Harzstark AL, Lo JC. PMID: 42869964 [PubMed - as supplied by publisher]
	Contemporary Oncological and Patient-reported Outcomes of Intravesical Gemcitabine/Docetaxel in BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Multi-institutional Prospective Cohort Study. Eur Urol Focus Tan YG, Dudinec J, Kamat AM, Lim BJH, Ghoreifi A, Yuen JSP, Chen K, Kanesvaran R, Chan J, Shah AM, Tay KJ, Abern MR. PMID: 42869744 [PubMed - as supplied by publisher]
	Response to "Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival". Urol Oncol Kohler J, Rodler S. PMID: 42869700 [PubMed - as supplied by publisher]
	Transitioning from template-based groin dissection to dynamic sentinel node biopsy in penile cancer: Prospective validation of a standardization step. Urol Oncol Prakash G, Shaikh S, Arora A, Pal M, Misra A, Gujela A, Bakshi G, Rangarajan V, Agrawal A, Menon S. PMID: 42869699 [PubMed - as supplied by publisher]
	Initial complete local therapy without systemic therapy versus systemic-therapy-based management in selected patients with oligometastatic renal cell carcinoma: a matched comparative study. Radiother Oncol Kim HU, Lee HI, Park I, Kim JK, Kim YJ. PMID: 42869248 [PubMed - as supplied by publisher]
	Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study. J Natl Compr Canc Netw Gopalakrishnan D, Fujiwara Y, Collier KA, Park JJ, Zaemes JP, Lam ET, Alaklabi S, Jaeger EB, Barata PC, Kauffman EC, Atkins MB, Alva A, Yang Y, George S. PMID: 42869085 [PubMed - as supplied by publisher]
	[Molecular-Based Diagnostics and Therapy of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)]. Aktuelle Urol Kesch C, Hadaschik B, von Amsberg G. PMID: 42869040 [PubMed - as supplied by publisher]
	Adenoma laterality and risk of subsequent colorectal cancer: Secondary analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer trial. Surgery Frebault J, Troester A, Huo L, Rudser K, Hassan I, Shaukat A, Goffredo P. PMID: 42868921 [PubMed - as supplied by publisher]
	Real-World Tumor-Informed Circulating Tumor DNA Dynamics and Survival Associations in Advanced Urothelial Cancer Treated With First-Line Enfortumab Vedotin and Pembrolizumab. JCO Precis Oncol Nimgaonkar V, Arbuiso A, Vlachou E, Johnson BA, Smith A, Kates M, Patel S, Singla N, Russell S, Rourke K, Elias R, Matoso A, Baraban EG, Hahn NM, Hoffman-Censits J. PMID: 42868336 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 182166

Page 1 of 9109



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy